A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice.
A monoclonal antibody to human angiogenin suppresses tumor growth in athymic mice.
复制标题
人血管生成素单克隆抗体可抑制无胸腺小鼠的肿瘤生长。
作者：
K. Olson;T. C. French;B. Vallée;J. Fett
HT-29结肠腺癌细胞分泌的血管生成素是一种有效的血管生成诱导剂。微克剂量的中和血管生成素的体外和体内活性的单克隆抗体预防或延迟s.c. HT-29肿瘤在无胸腺小鼠中以统计学显著的剂量依赖性方式。该抗体在体外对肿瘤细胞没有细胞毒性，这表明肿瘤生长的抑制最有可能通过中和血管生成素在体内的活性而发生，并进一步暗示血管生成素在HT-29肿瘤的早期发展中的关键作用。结果表明，一种治疗上有用的方法来治疗血管生成素依赖性恶性肿瘤。
Human angiogenin, a potent inducer of neovascularization, is secreted by HT-29 colon adenocarcinoma cells. microgram doses of a monoclonal antibody that neutralizes the in vitro and in vivo activities of angiogenin prevent or delay the appearance of s.c. HT-29 tumors in athymic mice in a statistically significant, dose-dependent manner. The antibody is not cytotoxic to tumor cells in vitro, which indicates that inhibition of tumor growth most likely occurs by neutralization of the activity of angiogenin in vivo and further implies a critical role for angiogenin in the early development of HT-29 tumors. The results suggest a therapeutically useful approach to the treatment of angiogenin-dependent malignancy.